(Q48418075)

11 February 2018

title

OnabotulinumtoxinA (BOTOX®): a guide to its use in preventing headaches in adults with chronic migraine (English)

1 reference

11 February 2018

Katherine A Lyseng-Williamson

1 reference

botulinum toxin type A

1 reference

0 references

series ordinal

1

1 reference

11 February 2018

author name string

James E Frampton

series ordinal

2

1 reference

11 February 2018

publication date

1 August 2012

1 reference

11 February 2018

published in

CNS Drugs

1 reference

11 February 2018

volume

26

1 reference

11 February 2018

issue

8

1 reference

11 February 2018

page(s)

717-723

1 reference

11 February 2018

https://scigraph.springernature.com/pub.10.2165/11208930-000000000-00000

exact match

0 references

cites work

Migraine with aura: conventional and non-conventional treatments

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

Chronic migraine, classification, differential diagnosis, and epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

New appendix criteria open for a broader concept of chronic migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

A review of current European treatment guidelines for migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

Taking the negative view of current migraine treatments: the unmet needs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

Updates on the antinociceptive mechanism hypothesis of botulinum toxin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

Botulinum neurotoxin for pain management: insights from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

Insights into the mechanism of onabotulinumtoxinA in chronic migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

Clinical relevance of botulinum toxin immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

Meta‐analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

A double-blind comparison of onabotulinumtoxina (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

Licence for Botox in so-called chronic migraine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208930-000000000-00000

OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial

21 January 2018

1 reference

12 December 2020

Increased levels of SV2A botulinum neurotoxin receptor in clinical sensory disorders and functional effects of botulinum toxins A and E in cultured human sensory neurons

1 reference

12 December 2020

A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine

1 reference

12 December 2020

OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program

1 reference

12 December 2020

OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial

1 reference

12 December 2020

10.2165/11208930-000000000-00000

Identifiers

DOI

1 reference

11 February 2018

Dimensions Publication ID

1014863612

0 references

1 reference

11 February 2018